The clinical question the flight data can and cannot answer
In terrestrial disuse osteoporosis—after spinal cord injury, during prolonged immobilization, or across extended bed rest—clinicians face a practical question: if mechanical loading is already prescribed, does adding an antiresorptive produce meaningful additional protection, or does it mainly suppress a laboratory marker while the skeleton continues to lose structural integrity? The International Space Station bisphosphonate experiment is often cited as if it settled that question. It did not. What it did was provide a small, carefully instrumented signal that an antiresorptive can act as an adjunct to loading under conditions of profound unloading. That is a narrower and more useful claim than the one frequently attributed to it.
The distinction matters because disuse osteoporosis is not a single disease. The duration of unloading, the pattern of mechanical stress, nutritional status, age, gonadal status, and comorbidity burden all differ between an astronaut on a 5.5-month mission and a patient with a complete spinal cord injury. The flight experiment is best read as a mechanistic bridge—hypothesis-generating for terrestrial care, not a transferable protocol.
What the experiment was
The bisphosphonate study was a collaboration between NASA and JAXA designed to test whether an antiresorptive drug combined with in-flight exercise would reduce bone loss and hypercalciuria during long-duration spaceflight. The investigators framed elevated bone resorption as a hallmark of both spaceflight and bed rest, which they described as a common zero-gravity analog (LeBlanc et al., NTRS 20140003448).
The published cohort was seven ISS astronauts who spent a mean of 5.5 months on station and took 70 mg of oral alendronate weekly, beginning three weeks before flight and continuing through the mission. All crewmembers had access to a treadmill, cycle ergometer, and resistance exercise device. Assessments included dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) across multiple bone regions, plus assays of bone metabolism biomarkers (LeBlanc et al., Osteoporosis International, 2013).
The comparison groups are important to describe precisely. The treated crew used the Advanced Resistive Exercise Device (ARED). They were compared with 18 astronauts who flew ISS missions using the earlier interim resistive exercise device and with 11 ISS astronauts who exercised using ARED. The NTRS abstracts also describe concurrent untreated controls using ARED, with immediate postflight data available for five of ten controls in the 2014 report and six of ten in the 2015 update (NTRS 20140003448; NTRS 20140014060). This was not a large randomized trial with a fully analyzed concurrent control arm. It was a small flight cohort compared against historical and partially analyzed concurrent controls.
What the data supported
The investigators reported that the combination of ARED and alendronate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight. That included DXA-determined losses in bone mineral density of the spine, hip, and pelvis; QCT-determined compartmental losses in trabecular and cortical bone mass in the hip; calculated measures of fall and stance computed bone strength of the hip; elevated bone resorption markers; and urinary calcium excretion (LeBlanc et al., 2013).
The one-year follow-up data extended the signal: bone measures for treated subjects remained at or near baseline values, and except in one region the treated group maintained or gained bone one year after flight (NTRS 20140003448). The authors’ conclusion was appropriately hedged: the combination of exercise plus an antiresorptive drug may be useful for protecting bone health during long-duration spaceflight (LeBlanc et al., 2013).
The ARED-alone result is equally instructive. ARED provided significant attenuation of bone loss compared with the older device, but postflight decreases in the femoral neck and hip remained (LeBlanc et al., 2013). The 2015 update put a number on it: ARED prevented about half the bone loss seen in early ISS crewmembers, and adding an antiresorptive provided additional benefit (NTRS 20140014060). Resorption markers and urinary calcium excretion were not impacted by exercise alone but were significantly reduced with antiresorptive treatment (NTRS 20140014060).
That pattern—loading helps structure, antiresorptive helps remodeling—is mechanistically coherent. Mechanical loading provides a strain signal that favors bone formation and orientation; antiresorptives reduce the resorptive arm of remodeling. In a state of unloading, loading alone may not fully suppress resorption, and an antiresorptive alone does not replace the mechanical signal. The combination hypothesis is biologically plausible. Plausibility, however, is not proof of interaction.
Where the evidence boundary sits
Three outcomes are often conflated in discussions of this experiment. The flight data treat them differently.
Bone mineral density attenuation is supported. DXA and QCT measures improved relative to expected declines, and the treated cohort remained near baseline at one year.
Resorption-marker reduction is supported. Biomarkers and urinary calcium fell with alendronate but not with exercise alone.
Fracture prevention is not addressed. The retrieved sources report no fracture endpoints, and a cohort of seven astronauts could not meaningfully assess fracture risk even if events had occurred. Attenuating a surrogate marker is not the same as preventing a clinical fracture.
There is a second boundary: the study was not designed or powered to isolate an interaction effect. The phrase “additional benefit” in the NTRS update describes an observed pattern across small groups, not a formally tested superiority of combination therapy over ARED alone. A trial powered to detect interaction would need a factorial design, adequate sample size per cell, and a prespecified interaction analysis. The flight experiment had none of these in the conventional sense. Its value lies in signal detection under conditions that cannot be reproduced on the ground.
Translating to terrestrial disuse osteoporosis—carefully
The investigators themselves invoked bed rest as the common analog for spaceflight bone loss (NTRS 20140003448). That analogy is useful but imperfect. Spaceflight combines unloading with a unique radiation environment, fluid shifts, altered nutrition, and psychological stress. Terrestrial disuse often combines unloading with inflammation, spasticity, autonomic dysfunction, and variable access to rehabilitation. The magnitude and time course of bone loss differ. Recovery trajectories differ. A finding in astronauts should therefore be treated as a rationale for a terrestrial trial, not as evidence that the terrestrial trial has already been done.
What would a terrestrial trial need? At minimum: a defined disuse population, a standardized loading intervention, a prespecified antiresorptive agent and dose, a concurrent control arm, and endpoints that include both areal and volumetric bone density, bone strength estimates, and—where feasible—fracture or fragility outcomes. It would also need to address the practical problem that antiresorptives are not benign in all disuse populations; clinicians must weigh gastrointestinal, renal, and rare adverse effects against a benefit that has not yet been demonstrated in their specific patient group.
The ARED-alone finding is clinically instructive here. Mechanical loading helped, but femoral neck and hip deficits persisted. That is a rationale for studying adjuncts in patients who cannot achieve adequate loading—not proof that any particular patient should receive one. The clinician reading this literature should ask whether the combination has been tested against loading alone in a population resembling theirs, with endpoints that matter to them. For most terrestrial disuse populations, that trial has not yet been reported in the retrieved sources.
Reading the evidence as a clinician
The practical takeaway is methodological. When a study reports that a combination “attenuated” a decline, ask three questions. First, what was the comparator—historical controls, a concurrent untreated group, or a loading-alone group? Second, was the study powered to detect an interaction, or does “additional benefit” describe a pattern across small groups? Third, what endpoint was measured—density, a biomarker, or a clinical event? The ISS bisphosphonate experiment answers the first two in ways that limit inference and the third in ways that stop short of fracture prevention.
None of this diminishes the experiment. It was a difficult study conducted in an environment where sample size is constrained by the number of humans in orbit. It produced a coherent, mechanistically plausible signal that antiresorptives can complement mechanical loading under unloading conditions. That signal deserves follow-up in terrestrial disuse populations. It does not deserve to be cited as proof that the terrestrial question is settled.
Frequently asked questions
Did the ISS experiment prove that combining alendronate with ARED is better than ARED alone?
No. The investigators reported that adding an antiresorptive provided additional benefit relative to ARED alone, but the study was not designed or powered to formally test an interaction effect. The treated cohort was seven astronauts, and the concurrent control biomarker data were described as pending or incomplete in the retrieved abstracts (NTRS 20140003448; NTRS 20140014060).
Does the experiment support using alendronate in patients with disuse osteoporosis?
It supports studying the combination in terrestrial disuse populations. It does not establish a dosing regimen, a patient-selection rule, or a fracture benefit for those populations. The published conclusion was that exercise plus an antiresorptive may be useful for protecting bone health during long-duration spaceflight (LeBlanc et al., 2013).
Why does the ARED-alone result matter?
Because it shows that mechanical loading attenuated but did not eliminate bone loss at the femoral neck and hip (LeBlanc et al., 2013). That residual deficit is the clinical rationale for investigating adjuncts—not evidence that any specific adjunct is already proven in terrestrial care.
Is bed rest a valid analog for spaceflight bone loss?
The investigators described bed rest as a common zero-gravity analog (NTRS 20140003448). It is a useful bridge for hypothesis generation, but the two conditions differ in duration, loading pattern, nutrition, comorbidity, and recovery. Findings should be translated with those differences in view.
Primary sources
- LeBlanc A, Matsumoto T, Jones J, et al. Bisphosphonate ISS Flight Experiment. NASA Technical Reports Server, JSC-CN-30935, 2014. https://ntrs.nasa.gov/citations/20140003448
- LeBlanc A, Matsumoto T, Jones J, et al. Update of Bisphosphonate Flight Experiment. NASA Technical Reports Server, JSC-CN-32238, 2015. https://ntrs.nasa.gov/citations/20140014060
- LeBlanc A, Matsumoto T, Jones J, et al. Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. Osteoporosis International. 2013;24:2105–2114. https://link.springer.com/article/10.1007/s00198-012-2243-z